Genes predict response of adult leukemia patients to chemotherapy

March 19, 2004

(WASHINGTON, DC, March 19, 2004) - Genes can indicate which adult leukemia patients will respond to therapy and what the duration of their remission will be, according to a new study published in the April 1, 2004, issue of Blood, the official journal of the American Society of Hematology. Researchers from the Dana-Farber Cancer Institute in Boston, Mass., and the University "La Sapienza" in Rome studied 33 patients that had all been recently diagnosed with adult T-cell acute lymphocytic leukemia (T-ALL), a type of cancer in which the body makes too many T lymphocytes.

"The present study investigates, for the first time, the identification of gene expression profiles associated with both short-term and long-term outcome in adult patients with T-ALL. While approximately 70 percent of pediatric patients with T-ALL have excellent long-term response to intensive chemotherapy, adult patients have a much less favorable outcome. Previously, this poor prognosis of adult T-ALL patients had not been attributed to specific genetic signatures," according to Jerome Ritz, M.D., of the Dana-Farber Cancer Institute, co-senior author of the study. Robin Foa, M.D., from the University "La Sapienza," also served as senior author.

Using microarray technology, a technique that can evaluate the expression of thousands of genes at once, researchers were able to compare the gene expression profiles of the patients who responded to chemotherapy to those who did not. Through gene expression profiling - a determination of which genes in a cell or group of cells are active - the scientists identified a single gene, IL-8, that was highly expressed in T-ALL cells that were resistant to treatment. Researchers also discovered a set of 30 genes that were highly expressed in leukemic cells from patients who achieved complete remission.

A model based on the expression of three genes - AHNAK, TTK, and CD2 - was also found to be highly predictive of the duration of remission, correctly classifying 71 percent of outcomes. The model was later verified by T-ALL samples taken from a separate group of 18 patients. Two conventional measures for predicting a patient's outcome - the white blood cell count and the degree of differentiation (a comparison of the similarity between cancerous cells and their normal counterparts) - were also examined and appeared to be less predictive than the three-gene expression model.

The results of the study may help doctors customize a T-ALL patient's treatment plan based on the individual's predicted response to therapy using these methods. Further exploration of these genes may also lead to new therapeutic targets for adult T-ALL.

According to Donald Miller, M.D., Ph.D., Professor in the Division of Hematology at the University of Louisville and Director of the James Graham Brown Cancer Center in Louisville, Ky., "This work represents one of the first applications of genomics to an important clinical problem. It provides strong evidence that genetic analysis will help us provide better care to patients with leukemia and other malignant diseases."

###This work was supported by the National Institutes of Health grant CA66996, the Ted and Eileen Pasquarello Research Fund, the Associazione Italiana per la Ricerca sul Cancro, the Instituto Superiore di Sanita, the Ministero dell'Istruzione, dell'Universita e della Ricerca Scientifica (MIUR), the Progetto FIRB, and the Associazione per le Leucemie Acute dell'adulto "Cristina Bassi" e Fondazione Cassa di Risparmio di Genova e Imperia.

To receive a copy of the study or to arrange an interview with Jerome Ritz, M.D., or Robin Foa, M.D., senior authors of the study, please contact Aislinn Raedy at 202-776-0544 or araedy@hematology.org.


The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers twice per month, available in print and online at www.bloodjournal.org.

American Society of Hematology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.